Among the three patients:One patient demonstrated tumour shrinkage that persisted for over 2 years and the sustained presence of TCR T cellsOne patient increased size of the target lesions before TBI‐1301 infusion and then decreased after infusionTwo CRS cases: grade 1, 2Patients with low expression NY‐ESO‐1 showed poorer response. Here, CTAG1B is linked to neoplasm.